Edwards Lifesciences Trading Volume Surges 74.97% to 184th Position as Boston Scientific Exits TAVR Market

On May 28, 2025, Edwards Lifesciences (EW) saw a significant increase in trading volume, with a turnover of 4.66 billion, marking a 74.97% rise from the previous day. This surge placed Edwards Lifesciences at the 184th position in terms of trading volume for the day. The stock price of Edwards Lifesciences rose by 0.58%, marking the third consecutive day of gains, with a total increase of 2.50% over the past three days.

Edwards Lifesciences' stock price surged on Wednesday following an announcement by Boston Scientific that it would cease selling its competing heart-valve replacement systems. This decision by Boston Scientific to discontinue the sales of its Acurate Neo and Acurate Neo2 transcatheter aortic valve replacement (TAVR) systems globally has provided a significant boost to Edwards Lifesciences' market position.

This strategic move by Boston Scientific is expected to have a positive impact on Edwards Lifesciences' market share, as it eliminates a key competitor in the TAVR market. The discontinuation of these products by Boston Scientific is likely to benefit Edwards Lifesciences, as it reduces competition and allows the company to capture a larger portion of the market.